SCNN1B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL18538918	0.98	1/20
SCHEMBL18538914	0.90	1/20
SCHEMBL20348262	0.89	1/20
SCHEMBL18538913	0.85	1/20
SCHEMBL20032722	0.85	1/20
SCHEMBL18538896	0.83	1/20
SCHEMBL18541360	0.81	1/20
SCHEMBL18538902	0.81	1/20
SCHEMBL18538919	0.78	1/20
SCHEMBL20348260	0.78	1/20
SCHEMBL18538917	0.78	1/20
SCHEMBL18538924	0.76	1/20
SCHEMBL18538920	0.75	1/20
SCHEMBL18541357	0.74	1/20
SCHEMBL20032721	0.73	1/20
SCHEMBL18541249	0.73	1/20
SCHEMBL18538897	0.72	1/20
SCHEMBL18538899	0.71	1/20
SCHEMBL21444428	0.71	1/20
SCHEMBL18538911	0.70	1/20

Clinical trials — most relevant to SCNN1B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes	PHASE4	UNKNOWN
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy	PHASE3	COMPLETED
Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis	PHASE3	COMPLETED
Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis	PHASE1/PHASE2	COMPLETED
An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome	PHASE1/PHASE2	COMPLETED
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)	PHASE1/PHASE2	RECRUITING
StereoTactic Arrhythmia Radiotherapy in the NetherLands no. 2	PHASE2	RECRUITING
Factors Affecting Salt Intake in Young Adults	nan	UNKNOWN
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study	nan	UNKNOWN
Adverse Airway Effects From Tobacco and E-Cigarettes	nan	UNKNOWN
A Single Center Prospective Study in an Estimated 570 Patients Who Underwent Genetic Screening at UZ Brussel in the Context of a Primary Cardiac Arrhythmia. Patients Showing a Variant Class 3,4 or 5 in SCN4A or CLCN1 Will Undergo a Clinical and Electrophysiological Review After IC.	nan	NOT_YET_RECRUITING
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Double Blind Crossover Comparison of Diuretics in the Young	nan	UNKNOWN
EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype Heterogeneity	nan	UNKNOWN
SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom	nan	RECRUITING
A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy	nan	COMPLETED
Impaired Secretory IgA and Mucosal Immunity in Cystic Fibrosis	nan	UNKNOWN
Primary Nasal Cell Culture as a Tool for Personalized Therapy in Cystic Fibrosis	nan	COMPLETED
Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)	nan	COMPLETED
Energy Balance and Weight Gain With Ivacaftor Treatment	nan	COMPLETED
Hypertension and Urine Protease Activity in Preeclampsia	nan	COMPLETED
Cross-sectional and Prospective Study to Characterize Early-onset Presbycusis	nan	RECRUITING
Identifying Diuretic Resistance in Patients With Acute Heart Failure	nan	COMPLETED
fMRI-study in Patients With Small Fiber Neuropathy	nan	UNKNOWN
Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis	nan	COMPLETED
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a SCNN1B binder may also engage these)

Protein	Name	Similarity
Q95165	—	1.000	Q95165 →
P37090	—	1.000	P37090 →
A5D7U4	—	1.000	A5D7U4 →
Q9WU38	—	1.000	Q9WU38 →
O97742	—	0.998	O97742 →
K7FQW8	—	0.998	K7FQW8 →
SCNN1G	Epithelial sodium channel subunit gamma	0.997	landscape →
P51167	—	0.995	P51167 →
H2QAR5	—	0.995	H2QAR5 →
O62816	—	0.994	O62816 →
Q28738	—	0.993	Q28738 →
P37091	—	0.992	P37091 →
P51169	—	0.991	P51169 →
O13262	—	0.991	O13262 →
Q9WU39	—	0.990	Q9WU39 →
H1AFJ5	—	0.989	H1AFJ5 →
H2QAR6	—	0.988	H2QAR6 →
H1AFJ6	—	0.986	H1AFJ6 →
K7FSQ4	—	0.986	K7FSQ4 →
F1MJW3	—	0.986	F1MJW3 →
K7GET2	—	0.986	K7GET2 →
H1AFJ7	—	0.985	H1AFJ7 →
P51171	—	0.983	P51171 →
H9GBX2	—	0.982	H9GBX2 →
Q92075	—	0.981	Q92075 →
O13263	—	0.980	O13263 →
P24585	—	0.978	P24585 →
P24612	—	0.978	P24612 →
Q60NC0	—	0.976	Q60NC0 →
Q19038	—	0.973	Q19038 →